Nele Kindt
Leuven, VLG 3000, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma.
Journal: Biomedicines
Published: February 22, 2022
PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index.
Journal: Molecular cancer therapeutics
Published: June 10, 2021
AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.
Journal: Current eye research
Published: July 12, 2016
Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery.
Journal: Progress in brain research
Published: October 27, 2015
Design, synthesis and biological characterization of selective LIMK inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: May 22, 2015
Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.
Journal: Journal of medicinal chemistry
Published: April 22, 2015
The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.
Journal: Investigative ophthalmology & visual science
Published: January 29, 2015
3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: August 12, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026